NCT05220072View on ClinicalTrials.gov

Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 28, 2021

Primary Completion Date

October 16, 2021

Study Completion Date

October 16, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Carbon-14 BIA 28-6156

Carbon-14 BIA 28-6156 60 mg, containing NMT 3.7 MBq Carbon-14

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

All Listed Sponsors
lead

Bial R&D Investments, S.A.

INDUSTRY

NCT05220072 - Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156 | Biotech Hunter | Biotech Hunter